Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Published byAri Kusnadi Modified over 6 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Clin. Oncol. doi: /nrclinonc"— Presentation transcript:

1 Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.58
Figure 4 Management of immune-related adverse events excluding skin and endocrine toxicities Figure 4 | Management of immune-related adverse events excluding skin and endocrine toxicities. General guidelines for the management of immune-related adverse events attributed to checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or programmed cell death 1 (PD-1). Boutros, C. et al. (2016) Safety profiles of anti-CTLA‑4 and anti‑PD‑1 antibodies alone and in combination Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Nat. Rev. Clin. Oncol. doi: /nrclinonc"

Similar presentations

The Promise of Immunotherapy for Cancer Treatment

The Promise of Immunotherapy for Cancer Treatment
Figure 5. Treatment of the checkpoint inhibitor related toxicity

Figure 5. Treatment of the checkpoint inhibitor related toxicity
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 1 Radiation-induced effects on tumour cells

Figure 1 Radiation-induced effects on tumour cells
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Generations of cancer vaccine antigens

Figure 1 Generations of cancer vaccine antigens
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.
Figure 2 Signalling pathways and physiological domains that are

Figure 2 Signalling pathways and physiological domains that are
Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 2 Neoantigen presentation in the tumour microenvironment
Figure 1 Four nodes to target when inducing anti-tumour immunity

Figure 1 Four nodes to target when inducing anti-tumour immunity
Figure 2 Three-step approach to the assessment and management

Figure 2 Three-step approach to the assessment and management
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Chimeric antigen receptor (CAR) structures

Figure 1 Chimeric antigen receptor (CAR) structures

Similar presentations

Ads by Google